Revalia Bio raises $14.5M betting that revived human organs beat animal trials

Revalia runs 'human data trials' — pre-clinical drug tests on donated organs that are revived and kept functional outside the body — and sells the resulting safety and efficacy data to pharma companies

Perfused, revived human donor organs can replace animal models as the standard for pre-clinical drug testing

$5M pre-seed (SAFE notes) plus $14.5M seed

Greg Tietjen, a biophysicist and Yale assistant professor running an academic perfusion-science lab, left his tenure-track position in 2023 to spin Revalia out of the university, betting that reviving donor organs with proprietary perfusion technology could give drug developers 'predictive' human data that animal models never could.

Revalia spent its first year validating demand and pricing — a starter trial package plus a recurring subscription — while FDA and NIH moved to reduce reliance on animal testing for drugs like monoclonal antibodies. By its most recent year it had multimillion-dollar revenue and two top-10 pharma customers, which let it close a $14.5 million seed round co-led by America's Frontier Fund and Sierra Ventures, with participation from former Federal Reserve vice chair Roger Ferguson.

Tietjen had a decade of academic perfusion-science credibility, giving him access to donated organs and the technical grounding to make the pitch to pharma R&D buyers.

FDA and NIH policy was actively moving away from mandatory animal testing, turning a research niche into a regulatory-driven market.

Multimillion-dollar revenue and two top-10 pharma customers before the seed round closed gave investors proof the model could sell, not just a lab demo.

Regulatory shifts create windows for a technical founder to bet a tenure-track career on turning a research technique into a commercial data product.

As of the September 2025 raise, Revalia was launching the beta of its platform, running trials in kidney disease and oncology, and planning to expand into new diseases and applications such as medical device testing and adaptive clinical-trial support.